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Resumo
 
 
A LLC é a leucemia mais frequente no mundo ocidental e afecta maioritariamente 
indivíduos do sexo masculino de idades avançadas (Zwiebel et al., 1998).  
A doença tem um curso indolente e uma mediana de sobrevivência longa (Ray et al., 
1975). Os tratamentos disponíveis podem induzir a remissão da doença, no entanto na 
maioria dos doentes ocorre recaída. Consequentemente, a LLC continua a ser uma 
doença incurável (Jaffe et al., 2001).  
Esta doença do sistema hematopoiético resulta da acumulação de células-B maduras 
neoplásicas resistentes à apoptose no sangue periférico, na medula óssea e nos 
gânglios linfáticos (Bennett et al., 1989). 
O diagnóstico clínico requer a presença de uma linfocitose persistente no sangue 
periférico (> 5000 linfócitos /μl) durante um período mínimo de 3 meses, sendo um dos 
principais critérios utilizados para distinguir a LLC do linfoma linfocítico (“Small 
Lymphocytic Lymphoma”) (Cheson et al., 1996). Quando o tumor se encontra apenas 
nos gânglios linfáticos (linfadenopatia) ou outros tecidos como o baço ou o fígado 
(hepatosplenomegália), sem ocorrer envolvimento do sangue periférico (< 5000 
linfócitos /μl) (Jaksic et al., 2001) ou da medula óssea, os doentes são diagnosticados 
com linfoma linfocítico (Jaffe et al., 2001). Devido às suas semelhanças morfológicas, 
imunológicas e fenotípicas a mais recente classificação da Organização Mundial de 
Saúde (OMS) relativa às neoplasias hematológicas distingue a LLC da entidade 
designada por linfoma linfocítico apenas pela sua apresentação leucémica e baixa 
agressividade (Jaffe et al., 2001). A presença da doença nos gânglios linfáticos está 
associada a menores taxas de sobrevivência e de resposta às terapias. Por 
conseguinte, o linfoma linfocítico é uma manifestação mais agressiva e com pior 
prognóstico da doença (Jaksic et al., 2001). 
A presença de marcadores de superfície das células-B (nomeadamente CD19, CD20 e 
CD23) (Cheson et al., 1996), a ausência de hipermutação somática dos genes das 
cadeias pesadas das imunoglobulinas (Hamblin et al., 1999; Damle et al., 1999) e a 
existência de anomalias citogenéticas nos cromossomas 13 [del(13q14.1)], 
11[del(11q)], 6 [del(6q)],  17 [del(17p)]  e trissomia do cromossoma 12 (Döhner et al., 
2000), são características utilizadas no diagnóstico clínico e são habitualmente 
preditivas da progressão da doença. A expressão de ZAP-70 e CD38  pelas células 
neoplásicas está também associada a um pior prognóstico da doença (Matrai, 2005). 
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No embrião, os vasos sanguíneos surgem de novo a partir de precursores endoteliais 
do sistema hematopoiético. Este processo é denominado de vasculogénese (Risau, 
1995), em oposição à angiogénese que ocorre através da ramificação de novos 
capilares a partir de vasos pré-existentes, e ainda do alargamento, separação e fusão 
desses mesmos vasos, o que implica a proliferação de células endoteliais (Folkman et 
al., 1992). No organismo adulto, os novos vasos surgem apenas através da neo-
vascularização (angiogénese) (Hanahan et al., 1996), mas o papel de precursores 
endoteliais neste processo tem ultimamente sido reconhecido como essencial 
(Asahara et al., 1999; Urbich et al., 2004). Estas células precursoras derivadas da 
medula óssea são recrutadas para a circulação em situações de stress vascular, 
resultante da libertação de níveis elevados de factores pró-angiogénicos (VEGF) e 
incorporam os vasos neo-formados (Hanahan et al., 1996). A existência de 
progenitores em circulação é sinal de uma actividade pró-angiogénica intensa, que 
poderá relacionar-se com o estádio de desenvolvimento tumoral e a agressividade da 
doença, e determinar a sensibilidade a diversas formas de terapêutica (Kay et al., 
2002). Diversos estudos demonstraram que o crescimento e metástases de tumores 
sólidos são dependentes do processo angiogénico (Hanahan et al., 1996), já proposto 
em 1971 por Folkman et al. 
Embora o seu papel patofisiológico em tumores sólidos tenha sido extensivamente 
estudado, a importância da angiogénese nas neoplasias hematológicas foi 
demonstrada recentemente (Perez-Atayde et al., 1997; Kini et al., 2000). Um 
aumento da angiogénese (vascularização) foi demonstrado em Linfomas de não-
Hogdkin de células-B, nomeadamente na medula óssea e gânglios linfáticos de 
doentes diagnosticados com LLC (Chen et al., 2000; Kini et al., 2000). A síntese 
pelas células leucémicas de níveis elevados de factores pró-angiogénicos (VEGF), 
assim como a expressão nestas células de VEGF e dos seus receptores (VEGFR-
1/FLT-1 and VEGFR-2 /KDR) foram também fundamentais para demonstrar o 
aumento do processo angiogénico (Chen et al., 2000; Kini et al., 2000; Molica et al., 
2002).  
  
Com a finalidade de melhor compreender qual a importância dos processos 
angiogénico e vasculogénico em neoplasias hematológicas, nomeadamente na LLC e 
de contribuir para a identificação de factores moleculares/biológicos que permitissem a 
distinção entre as formas leucémica e linfomatosa desta doença, o principal objectivo  
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desta tese de mestrado foi a caracterização do perfil angiogénico e vasculogénico 
dos doentes com LLC. 
Esta caracterização tinha como principal hipótese a possível existência de diferenças 
entre as duas fases da doença em determinados parâmetros 
angiogénicos/vasculogénicos existentes em circulação e incorporados na medula 
óssea e gânglios linfáticos. 
O primeiro parâmetro angiogénico estudado foram os progenitores endoteliais 
existentes em amostras de sangue periférico dos doentes em estudo. Os doentes 
foram estratificados em 4 grupos, de forma a homogeneizar as amostras e a criar 
grupos comparáveis entre si: doentes com LLC sem tratamento vs. doentes com 
linfoma linfocítico sem tratamento e doentes com LLC sob tratamento vs. doentes com 
linfoma linfocítico sob tratamento. 
Para a caracterização e quantificação da percentagem destes EPC foi utilizada a 
imunofenotipagem por Citometria de Fluxo através de anticorpos monoclonais contra 
os marcadores específicos da superfície celular dos progenitores endoteliais CD133 e 
VEGFR-2(KDR). Os resultados sugerem que o grupo de doentes com linfoma 
linfocítico têm uma maior percentagem de EPC em circulação independentemente da 
situação clínica. 
O potencial de diferenciação destes progenitores em células endoteliais 
maduras foi posteriormente testado in vitro em ensaios de diferenciação através da 
utilização de células mononucleadas isoladas do sangue periférico. Os resultados 
sugerem que estes progenitores são funcionais nos doentes com LLC e linfoma 
linfocítico e que a sua diferenciação em células positivas para o factor de Von 
Willebrand pode sugerir uma contribuição destes EPC para a formação dos novos 
vasos (vasculogénese). 
 
O segundo parâmetro em estudo foram os níveis circulantes de factores 
angiogénicos (VEGF) em plasma de sangue periférico. A concentração dos níveis 
VEGF foi determinada por métodos de ELISA. Os resultados obtidos sugerem que os 
níveis de VEGF no plasma não estão relacionados com a fase da doença ou com a 
situação clínica dos doentes, visto que se verificaram níveis elevados de VEGF no 
grupo de doentes com linfoma linfocítico sob terapia e no grupo de doentes com LLC 
sem tratamento. 
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Outros parâmetros angiogénicos incorporados nos tecidos afectados pelas células 
neoplásicas foram também caracterizados em biópsias de medula óssea e de gânglios 
linfáticos dos doentes em estudo. 
A determinação da densidade microvascular (angiogénese) em secções 
histológicas foi realizada por imunohistoquímica para o factor de Von Willebrand. Os 
resultados sugerem um maior número de vasos medulares nas biópsias dos doentes 
com  linfoma linfocítico, o que poderá estar correlacionado com um fenótipo mais 
agressivo da doença. 
 
Outras características fenótipas da doença foram também observadas nomeadamente 
apoptose das células tumorais e expressão de CD38 por estas células nos 
tecidos afectados. Uma menor apoptose das células tumorais e uma maior 
expressão de CD38 foram observadas nas biópsias de medula óssea dos doentes 
com linfoma  linfocítico. Estes resultados podem predizer uma maior agressividade 
desta fase da doença, com pior prognóstico quando comparada com a fase leucémica. 
As células tumorais são por conseguinte mais resistentes à apoptose e expressam 
mais CD38. Em estudos anteriores, foi demonstrado que doentes com uma maior 
expressão de CD38 pelas células neoplásicas tinham um pior prognóstico e uma 
menor sensibilidade às terapias (Matrai, 2005).    
 
O perfil de expressão de miRNAs foi caracterizado em células mononucleadas 
isoladas do sangue periférico de doentes com LLC e linfoma linfocítico. Os resultados 
revelaram que existem diferentes perfis de expressão de miRNAs associados com as 
duas formas da doença. 
 
Em suma, o trabalho desenvolvido durante este projecto de mestrado revelou pela 
primeira vez a existência de diferenças significativas entre as duas fases da doença 
(LLC vs. linfoma linfocítico) em determinados parâmetros angiogénicos e 
vasculogénicos existentes em circulação e incorporados nos tecidos-alvo da doença. 
Estas diferenças foram sugeridas por uma maior percentagem de progenitores 
endoteliais em circulação nos doentes com linfoma linfocítico em relação aos doentes 
com LLC. Este resultado juntamente com o aumento da densidade microvascular 
observada nas biópsias de medula óssea dos mesmos doentes podem ser 
correlacionados com um fenótipo mais agressivo. Este fenótipo pode também estar  
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relacionado com a maior resistência à apoptose e maior expressão de CD38 
observadas. 
 
Entre as duas fases da doença (CLL and SLL)  verificou-se diferente expressão de 
miRNAs e o possível significado biológico desta diferença será explorado em 
experiências futuras  . 
 
Palavras-Chave: 
 
Angiogénese; Vasculogénese; Leucemia Linfocítica Crónica; Linfoma Linfocítico; 
Progenitores Endoteliais; Densidade microvascular. 
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Abstract
 
 
During tumor angiogenesis bone marrow (BM)-derived endothelial progenitor cells 
(EPC) are recruited to circulation and contribute to the neo-vasculature of growing 
tumors. Although the pathophysiologic role of angiogenesis in solid tumors has been 
extensively studied, its involvement in hematological malignancies has only recently 
been recognized. Increased angiogenesis has been documented in patients with 
Chronic Lymphocytic Leukemia (CLL). 
The World Health Organization classification of hematopoietic neoplasias recognizes 
some lymphomas and corresponding lymphoid leukemias as different phases (solid 
and circulating, respectively) of the same disease: CLL as a leukemic, lymphocytic 
lymphoma, only distinguishable from small lymphocytic lymphoma (SLL) by its 
leukemic presentation and lower aggressiveness. It arises mainly from a slow 
accumulation of mature-looking malignant B lymphocyte population resistant to 
apoptosis, in the peripheral blood (PB), BM and/or lymph nodes (LN). 
Given the clinical importance of distinguishing leukemic from lymphoma forms of CLL, 
we characterized the angiogenic and vasculogenic profile of CLL patients to test 
the hypothesis that there might be differences in angiogenesis-related parameters in 
circulation (circulating endothelial progenitor cells (CEPC) and vascular endothelial 
growth factor (VEGF) and incorporated into the affected BM and LN tissues between 
the two phases of the disease. 
Our data shows that patients with SLL under treatment have higher number of 
circulating EPC and higher levels of circulating VEGF. Importantly, we show that CEPC 
are functional in CLL and SLL patients, as seen in vitro in endothelial differentiation 
assays. We also observed increased microvessel density, decreased tumor cell 
apoptosis and higher CD38 expression by the tumor cells in BM biopsies from SLL 
patients which could be related with increased aggressiveness and bad prognosis of 
the disease at this phase. 
The miRNAs expression profile showed that there are different miRNAs patterns 
associated with SLL and CLL phases.  
Our study demonstrates for the first time significant differences in angiogenic and 
vasculogenic factors in circulation and in the affected tissues between leukemia and 
lymphoma phases, as suggested by a significant higher number of CEPC in SLL 
patients vs. CLL patients; this result together with increased MVD observed in BM of 
SLL patients could be related with a more aggressive phenotype. 
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Key-Words: 
 
Angiogenesis; Vasculogenesis; Chronic Lymphocytic Leukemia; Small Lymphocytic  
Lymphoma; Endothelial Progenitor Cells; Microvessel Density. 
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Aims of the thesis
 
 
With the purpose of expanding our knowledge on the importance of the 
angiogenic/vasculogenic process in hematologic neoplasias, namely in Chronic 
Lymphocytic Leukemia and given the clinical value of distinguishing leukemic from 
lymphoma forms/phases of this disease (CLL vs. SLL), the main purpose of this thesis, 
was the characterization of the angiogenic and vasculogenic profile of CLL 
patients. We tested if there were differences in angiogenesis-related parameters in 
circulation and incorporated into the affected tissues (BM and LN) between CLL and 
SLL.  
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Introduction
 
1. Lymphoid Neoplasms 
 1.1. Non-Hodgkin Lymphomas 
“The first description of what we now recognize as a lymphoma is 
generally attributed to Thomas Hodgkin in 1832”. 
 
1.2. World Health Organization (WHO) Classification 
 
In the last few decades, with the improvements in molecular biology, genetics 
and immunology, the classification of lymphoid tumors suffered extensive changes. 
The WHO classification distinguishes tumors primarily by cell lineage defined by 
immunophenotype and groups together lymphomas and leukemias, recognizing that 
some solid tumors also pass through circulating leukemic phases (Parkin et al., 2005). 
Therefore some lymphomas and corresponding lymphoid leukemias are recognized as 
different phases (solid and circulating, respectively) of the same disease (Morton et 
al., 2007).  
Lymphoid neoplasms, including lymphoma, myeloma and lymphoid leukemia, arise 
from the malignant transformation of lymphoid cells at various stages of differentiation 
and comprise the sixth most common group of malignancies worldwide in men and 
women (Parkin et al., 2005). 
Within the lymphoid neoplasms, the WHO system distinguishes Hodgkin lymphoma 
from non-Hodgkin lymphomas (NHL) based on morphologic and immunologic 
characteristics (Morton et al., 2007). The various NHL subtypes are distinguished in B-
cell NHL, T-cell NHL (including natural killer (NK)-cell NHL) and NHL of unknown cell 
lineage (Parkin et al., 2005) based on the stage of differentiation and additional 
morphologic, phenotypic, genotypic and clinical features (Jaffe et al., 2001). These 
categories are then classified by stage of differentiation into mature B-cell NHL, mature 
T-cell NHL and precursor cell NHL. The mature B-cell origin includes Chronic 
Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma the model study of this 
thesis. 
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2. Non-Hodgkin Lymphomas 
2.1. Chronic Lymphocytic Leukemia 
2.2. Small Lymphocytic Lymphoma 
 
“One disease at different phases, not two separate entities” (Jaffe et al., 2001) 
 
The first broad characterization of B and T cells soon led to the recognition that 
CLL is a disease of neoplastic B cells. In the beginning of the 1970s some clinical and 
pathological classifications began to integrate CLL within the category of diffuse, low-
grade, B-cell, non-Hodgkin lymphoma (Bennett et al., 1989).  
CLL is the most frequent type of leukemia in the Western world and affects mainly 
elderly individuals, but about one third of patients are less than 60 years of age at 
diagnosis (Zwiebel et al., 1998) and the number of cases increases exponentially in 
the aged. 
CLL follows an extremely variable course, with survival ranging from months to 
decades (Ray et al., 1975) and some patients have none or minimal symptoms during 
their entire disease course (Dighiero et al., 1991). However, in other cases, the 
disease may progress or be severe from the onset, necessitating immediate treatment 
(Dighiero et al., 1991). Available treatments can often induce disease remission, 
though nearly all patients relapse, and there is consensus that CLL remains an 
incurable disease (Jaffe et al., 2001). 
This disease arises mainly from a slow accumulation of mature-looking malignant 
monoclonal B cells resistant to apoptosis in peripheral blood (PB), bone marrow (BM) 
and lymph nodes (LN) (Bennett et al., 1989).  
The clinical diagnosis requires the presence of lymphocytosis (at least 5000 
lymphocytes/μL blood) in the PB during at least 3 months, in part to separate CLL from 
small lymphocytic non-Hodgkin's lymphoma (SLL). The clonality of the circulating B 
lymphocytes needs to be confirmed by flow cytometry. The leukemic cells found in the 
blood smear are characteristically small, mature lymphocytes with a narrow border of 
cytoplasm and a dense nucleus lacking discernible nucleoli and having partially 
aggregated chromatin. These cells may be found admixed with larger or atypical cells, 
cleaved cells or prolymphocytes (Cheson et al., 1996). At an advanced disease stage 
patients present infections, enlarged nodes (lymphadenopathy), splenomegaly and/or  
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hepatomegaly (with palpable lymph nodes or not), disease-related anemia or 
thrombocytopenia (Cheson et al., 1996).  
Molecular and cellular markers that may be used to predict disease progression have 
been identified. In particular, the mutational profile of immunoglobulin genes (Hamblin 
et al., 1999; Damle et al., 1999) and some cytogenetic abnormalities (Döhner et al., 
2000) show strong prognostic value. However, these biological differences do not 
separate CLL into two different disorders; it remains one disease with heterogeneous 
features (Hamblin, 2002). Consequently, it is clear that patients with CLL share a 
common and characteristic profile of gene expression despite heterogeneity in 
presentation and clinical disease course (Rosenwald et al., 2001).  
The predominant population found in CLL patients shares B-cell surface antigens 
(CD19, CD20 and CD23) with the T-cell antigen CD5 and each clone of leukemia cells 
is restricted to expression of either kappa or lambda immunoglobulin light chains 
(Cheson et al., 1996). These B cells also express surface immunoglobulin (slg), 
CD79b and CD22 with low density (Ginaldi et al., 1998). The most common deletions 
are in the long arm of chromosome 13 [del(13q14.1)]. Additional frequent chromosomal 
aberrations include trisomy of chromosome 12, deletions in the long arm of 
chromosomes 11 [del(11q)] or 6 [del(6q)], or in the short arm of chromosome 17 
[del(17p)] (Döhner et al., 2000). These characteristics are generally adequate for a 
precise diagnosis of CLL, and they also distinguish this disease from other disorders 
such as prolymphocytic leukemia, hairy-cell leukemia, mantle-cell lymphoma, and other 
lymphomas that can mimic CLL (Dighiero, 2003).  
When the tumor is confined to LN or other tissues (e.g. spleen and liver) without blood 
or BM involvement, patients are considered to have SLL; histology and 
immunophenotype are identical to CLL, and so the recommend management is the 
same (Jaffe et al., 2001).  
The definition of SLL entails the presence of lymphadenopathy and/or splenomegaly, 
the diagnosis being confirmed by histopathologic evaluation of a LN biopsy whenever 
possible. Moreover, the number of B lymphocytes in the PB should not exceed 5000 
lymphocytes/μL (Jaksic et al., 2001).  
Based on their similar morphological and immunophenotypic features, the most recent  
WHO classification of hematopoietic neoplasias considers CLL and SLL to be different 
manifestations of the same disease and combines these entities into one disease 
category (CLL/SLL) (Jaffe et al., 2001). This classification describes CLL as leukemic, 
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lymphocytic lymphoma, being only distinguishable from SLL by its leukemic 
presentation and lower aggressiveness (Jaffe et al., 2001).  
The prevalence of disease presentation at organ and lymph node level is associated 
with a less favorable outcome in terms of both response rate and overall survival 
(Jaksic et al., 2001), and therefore SLL is considered a more aggressive form of the 
disease with a worse prognosis. 
 
 
 
2.3. Prognostic factors (Ig VH Gene Mutation Status, CD38 and ZAP-70 
expression and cytogenetic abnormalities) and disease progression 
 
New biological prognostic factors have become increasingly important to 
understand CLL progression. The leukemic cells express Ig that may or not have 
incurred somatic mutations in the Ig heavy chain variable region genes (Ig VH genes). 
The outcome of patients with leukemic cells that use an unmutated IgVH gene is worse 
than that of those patients with leukemic cells that use a mutated IgVH gene. CLL 
cases with unmutated IgVH have a distinctly more malignant disease, with faster 
disease progression and shorter survival times than those with somatic mutations 
(Hamblin et al., 1999; Damle et al., 1999). CLL cells with trisomy 12 have atypical 
morphology and patients have an aggressive clinical course and poorer survival than 
those with abnormalities at 13q14; this point to an association between clinical status 
and degree of somatic mutation (Döhner et al., 2000). In addition, patients with tumor 
cells that express 70-kD zeta-associated protein (ZAP-70) and CD38 appear to have a 
worse prognosis. CD38+ CLL cells are characterized by a greater proliferative potential 
and by diminished sensitivity to chemotherapy (Matrai, 2005). 
Nevertheless, these molecular features of CLL still do not allow distinguishing 
lymphoma from leukemic phases of the disease. 
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2.4. Phenotypic features of CLL: Apoptosis 
 
In the majority of patients, CLL cells are predominantly G0 quiescent cells that 
gradually accumulate throughout the body, not because they are dividing more rapidly 
than normal, but because they are surviving too long.  However, it has been reported 
that CLL cells have deregulated expression of genes involved in apoptosis, and not in 
those involved in cell cycle progression. It is currently assumed that CLL cells are 
characterized by deregulation of the apoptosis pathway, which leads to increased cell 
survival and chemoresistance, although the aberration is not yet clear (Reed, 1999). 
The assessment of tumor cell apoptosis and the importance of this cell feature in the 
distinction between SLL and CLL are still unknown. 
 
 
 
3. Phenotypic features of tumors: Blood vessels formation  
3.1. Angiogenesis  
 3.2. Vasculogenesis (Embryonic vasculogenesis) 
 
Development of tumors is a highly complex process in which several molecular 
events are required for tumor cells to achieve independent growth. One such event is 
the angiogenic process (Hanahan et al., 2000). The increase in tumor mass during the 
initial stages of tumor growth results in a reduction of the oxygen levels within the 
expanding tissue (hypoxia), which leads to the production of pro-angiogenic growth 
factors, such as vascular endothelial growth factor (VEGF) (Hanahan et al., 1996), by 
the neoplastic cells.  
Blood vessels are fundamentally composed of endothelial cells, which interconnect to 
form the tubes that direct and maintain blood flow and tissue perfusion (Risau, 1995).  
During embryogenesis, blood vessels develop via two processes: vasculogenesis, 
which refers to the de novo formation of blood vessels by endothelial cells that arise 
from progenitor cells (Risau, 1995); and angiogenesis, in which new capillaries sprout 
from pre-existing vessels and also by the enlargement, separation and fusion of the  
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same vessels due to the proliferation and migration of activated endothelial cells (EC) 
(Folkman et al., 1992) (Figure 1).  
 
 
 
Figure 1. Blood vessel formation by postnatal vasculogenesis and angiogenesis. 
Recruitment of endothelial cells from preexisting vessels plays a critical role in the 
regulation of angiogenesis. BM-derived EPC with high proliferative capacity may have the 
potential to home and incorporate into sites of vascular injury or in tumor tissue 
(vasculogenesis). Image from Raffi S. The Journal of Clinical Investigation 2000, 105(1):17-
19. 
 
In the adult, new vessels are produced mainly through angiogenesis (Hanahan et al., 
1996) and once the definitive network is established, EC remain quiescent with 
neovascularization only occurring during physiological (during growth and in the female 
reproductive organs during ovulation, menstruation, implantation and pregnancy) or 
pathological events (tumor growth and wound healing). However, the presence of 
circulating EC or endothelial progenitor cells in the adult is now well established and 
lately the role of endothelial precursors has been recognized as essential in certain 
angiogenic processes (Asahara et al., 1999b; Urbich et al., 2004).  
In 1971, Folkman et al. proposed that tumor growth and metastasis are angiogenesis-
dependent, and so, that blocking angiogenesis should be considered a strategy to 
arrest tumor development. Without blood vessels, tumors cannot grow beyond a critical 
size or metastasize (Folkman et al., 1992). A considerable body of research spanning  
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more than three decades has documented that tumor growth and metastasis formation 
require new blood vessel growth. 
 
 
 
3.3. Postnatal Vasculogenesis (BM-derived EPC) 
 
During embryonic development, there is a close relationship between the 
development of blood cells and endothelium, indicating that hematopoietic cells (HC) 
and EC derive from a common progenitor, the hemangioblast, a transient cell stage 
that develops early and disappears quickly (Flamme et al., 1992).  
The thought that vasculogenesis is not restricted to embryogenesis, but also plays a 
role in postnatal physiological and pathological angiogenesis, arose from several 
studies performed in the first half of the 20th century. During tumor angiogenesis bone 
marrow (BM)-derived endothelial progenitor cells (EPC) are recruited in to the 
circulation in response to vascular stresses and contribute to the neo-vasculature of 
growing tumors (Asahara et al., 1999a; Asahara et al., 1999b). These cells leave the 
BM and enter the vasculature in response to an increase in the levels of circulating 
angiogenic factors such as VEGF (Figure 2). Once in the circulation, EPC can arrest at 
sites of ischemia or growth factor release (such as VEGF release), such as in the 
tumor periphery. These cells can then participate in new vessel formation by 
differentiating into branching blood vessels (Asahara et al., 1999a; Garmy-Susini et 
al., 2005).  
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Figure 2. Bone marrow-derived EPC (purple circles) contribute to tumor 
angiogenesis. Image from Garmy-Susini B. et al., British Journal of Cancer 2005, 93:855-
858.  
 
The key regulators of vasculogenesis are VEGF and its receptors, VEGF receptor-1 
(VEGFR-1, also known as fms-like, Flt-1) and VEGF receptor-2 (VEGFR-2, also known 
as kinase insert domain-containing receptor, KDR in humans) with different signaling 
and biological properties (Neufeld et al., 1999).  
 
 
 
3.4. Biology of Endothelial Progenitor Cells 
 
The majority of EPC is thought to reside in the BM in close association with 
hematopoietic stem cells and the bone marrow stroma where the growth and  
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differentiation of hematopoietic cells and endothelial precursors occurs (Urbich 
et al., 2004). Besides their common precursor, hematopoietic stem cells (HSC) and 
angioblasts/EPC share certain antigenic determinants that are also endothelial-specific 
markers, including VEGFR-2 and VEGFR-1, CD31 and CD34 (adhesion molecules), 
von Willebrand factor (vWf; coagulation factor) and they also have the ability to 
incorporate acetylated low-density lipoprotein (Ac-LDL) (Asahara et al., 1999b; Raffi 
et al., 2003).  
EPC are maintained in an undifferentiated and quiescent state in the BM 
microenvironment and when stimulated they have the capacity to proliferate, migrate 
and differentiate into EC, but have not yet acquired characteristics of mature EC 
(Ribatti, 2004). Angiogenic factors as VEGF and its receptors may regulate the 
expression of adhesion molecules on EC and control the recruitment and migration of 
EPC to sites of vessel repair (Asahara et al., 1999a). Circulating EPC differ from the 
circulating EC that are randomly detached from the vessel walls and enter the 
circulation as a result of vascular injury. Moreover, when EPC were exposed to 
angiogenic factors, they form highly proliferative endothelial colonies, whereas 
circulating EC only generate endothelial monolayers with limited proliferation capacity 
because they are mature, terminally differentiated cells (Raffi, 2000; Raffi et al., 2003). 
EPC were first described in 1997 by Asahara et al. as CD34-enriched mononuclear 
cells that acquired endothelial surface marker expression in culture. Following studies 
showed that a subpopulation of circulating CD34+ cells expressing 
CD34+CD133+VEGFR2+ could form endothelial colonies in vitro (Peichev et al., 2000; 
Gill et al., 2001). Peichev et al., found that CD133 (a stem cell marker), is also 
expressed on subsets of CD34+ cells, its expression being downregulated (CD133-) 
when EPC differentiate into adherent mature EC; these cells then express endothelial 
specific markers, such as vWF and VE-cadherin. VEGFR-2 positive EPC were found to 
be present at low frequencies in human umbilical cord blood, adult BM, human fetal 
liver cells and cytokine-mobilized peripheral blood. When incubated in vitro with 
appropriate medium in the presence of specific growth factors, circulating EPC have a 
high proliferating potential and are able to produce colonies of cells expressing 
endothelial cell markers, such as CD34, CD133 and VEGFR-2, which this being the 
most widely used combination of surface markers for identifying human EPC (Asahara 
et al., 1999; Peichev et al., 2000; Ribatti, 2004). 
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4. Angiogenesis and Vasculogenesis in Hematologic Neoplasias 
 
Although the pathophysiologic role of angiogenesis in solid tumors has been 
extensively studied, its involvement in hematological malignancies has been 
recognized only recently. Because the BM and lymphatic organs are predominant sites 
for tumor cell accumulation in these malignancies, it was initially believed that 
angiogenesis would not be relevant in these tumors (Perez-Atayde et al., 1997; Kini 
et al., 2000).  
However, an early report from Perez-Atayde et al. 1997, showed that BM of children 
with acute lymphoblastic leukemia (ALL) have higher microvessel density as compared 
to normal controls. These children had also higher urine levels of the angiogenic 
peptide basic fibroblast growth factor (bFGF) when compared to normal controls. 
These results indicate that ALL cells are angiogenic and that angiogenesis plays a role 
in the pathogenesis of the disease (Perez-Atayde et al., 1997). Increased 
angiogenesis was also reported in the BM of patients with multiple myeloma. Myeloma 
cells secrete bFGF and stimulate angiogenesis in in vitro and in vivo angiogenesis 
assays (Vacca et al., 1999).  
In addition, there is increased angiogenesis in B cell non-Hodgkin lymphomas, which 
has been documented both in BM and LN of CLL patients (Chen et al., 2000; Kini et 
al., 2000).  Although the role of angiogenesis in CLL remains to be fully elucidated, 
experimental data suggest that several angiogenic factors play a role in the 
pathogenesis and survival of the B-cell clones and consequently in the disease 
progression. These findings were also supported by the presence of increased 
neovascularization in the BM and LN and by the expression of angiogenic factors as 
VEGF and its receptors (VEGFR-1/FLT-1 and VEGFR-2 /KDR) by CLL cells (Chen et 
al., 2000; Kini et al., 2000; Molica et al., 2002).  
CLL cells produce VEGF which, acting in an autocrine manner has an antiapoptotic 
effect on the CLL cells. This interplay of cytokines and their function is further 
elucidated by the active role of nearby stromal cells that produce hematopoietic growth 
factors under the influence of angiogenic factors. VEGF-based autocrine pathway 
promotes the survival of CLL B-cells through up-regulation of anti-apoptosis (Kay et 
al., 2002).  
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The contribution of EPC (vasculogenesis) to the formation of neo-vessels is belived to 
be particularly relevant in NH lymphoma, the presence of circulating EPC in these 
patients correlated with angiogenic activity during tumor growth (Peters et al., 2005).  
Igreja et al. 2007 observed for the first time that the existence of EPC already 
incorporated into affected LN or in circulation in lymphoma patients may be used to 
monitor disease progression, tumor aggressiveness or response to treatment. 
Therefore, the presence and clinical relevance of EPC in CLL biology, including their 
possible distinguishing role in CLL and SLL, is the focus of the present thesis.  
 
 
 
5. MicroRNA expression profiling in PB 
5.1. Implications in CLL 
 
MicroRNAs (miRNAs) are ssRNA (single-strand RNA) of 19–25 nucleotides (nt) 
in length that are generated from endogenous transcripts harboring local hairpin 
structures (Kim et al., 2005a). The miRNAs are transcribed from autonomous 
transcription units into pri-miRNAs (primary precursor miRNAs). The pri-miRNAs are 
then processed to release the precursor of miRNAs (pre-miRNAs). Following this 
nuclear processing, the pre-miRNAs are exported to the cytoplasm and again are 
processed to release the mature miRNA (Lee et al., 2004).  
MicroRNAs control several pathways including hematopoiesis, apoptosis, cell 
proliferation and tumorigenesis. The miRNAs are critical players in tumorigenesis 
where they can act directly as tumor suppressors or as oncogenes (oncomirs), or 
indirectly as consequence of the genetic and microenvironment pressures induced by 
the tumor (Kim 2005a; Kim 2005b). Therefore, miRNAs are involved in cancer 
initiation and progression and their expression profiling can be exploited for the 
classification, diagnosis and progression of human malignancies. The first report linking 
miRNAs and cancer was in CLL (Calin et al., 2002) and recent findings identify 
miRNAs as key players in pathogenesis of CLL. MiRNA expression profiling by 
microarrays allowed the identification of differentially expressed miRNA. For instance, a  
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cluster of two miRNAs, miR-15a and miR-16-1 are located in the main deleted region in 
CLL (13q14.3) and are known to target the anti-apoptotic BCL2 gene (Cimmino et al.,  
2005) which have potential for CLL prognosis: patients with good prognosis showed 
down-regulation of miR-15a and miR-16, whereas bad prognosis was associated with 
down-regulation of miR-29 (Calin et al., 2002; Calin et al., 2004). 
The miR-155 has been already described as the first miRNA linked to human disease, 
specifically in B-cell malignancies (Eis et al., 2005). High level of this miRNA is related 
to aggressive form of CLL (Calin et al., 2005) and its role is to induce polyclonal 
expansion (Constinean, 2006). The miR-451 is associated with erythroid maturation 
and may play a role in promoting it´s differentiation (Zhan et al., 2007). Although a 
signature associated with prognostic factors and CLL progression have been 
characterized (Cheson et al., 1996), differences in the miRNA expression between the 
CLL and SLL were not described.  
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Patients Classification 
 
Patients admitted to the Hematology Department, IPOLFG-EPE, and classified as CLL 
were divided into 4 groups according to the phase of the disease (leukemia vs. 
lymphoma presentation) and clinical treatment after the diagnosis (without treatment 
and under treatment, mostly with chemotherapy). (A detailed description of the patients 
is given in Supplementary Tables 1, 2, 3, 4). 
 
 
Samples 
 
From the 60 patients studied (47% female vs. 53% male, mean age 68.5 years) we 
collected PB samples with a volume of 2-3mL that were analyzed by different 
techniques. All the primary samples were collected after informed consent of the 
patients, according to IPOLFG-EPE guidelines. The processing of PB started with the 
plasma separation by centrifugation. After mononuclear cells (MNC) were separated 
and purified from PB samples by density gradient centrifugation (Lymphoprep™). 
We also obtained 44 paraffin embedded biopsies, 34 BM and 10 LN sections from the 
patients under study that were used for immunohistochemical staining. 
 
 
Immunophenotyping by Flow cytometry 
  
To perform flow cytometry analysis by fluorescence-activated cell-sorting (FACS) we 
used 100μL of PB sample (from a total of 2-3mL) ressuspended in 200μL of FACS 
buffer (PBS 1x, 2% FBS) and acquired the data corresponding to 50 000 cells in each 
sample. In order to identify EPC, immunofluorescent staining was performed, with the 
use of the following fluorescent conjugated antibodies: CD133-PE anti-human 
monoclonal antibody (Myltenyi Biotec) and anti-human monoclonal antibody KDR-APC  
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(R&D Systems, Inc). We analyzed the presence of circulating EPC (CD133+KDR+ 
cells) (CEPC) in each patient and we always used another 100μL of PB as control 
(without any EPC marker). Due to the rarity of this cell population, a patient’s sample 
was considered CEPC positive if both EPC markers CD133 and KDR were detected 
with a minimum percentage of 0, 01 events in 50000 cells. We analyzed 44 CLL 
patients (33 without treatment and 11 under treatment) and 16 SLL patients (8 without 
treatment and 8 under treatment). 
 
Enzyme-Linked Immunoabsorbent Assay (ELISA) 
 
VEGF levels were measured in plasma of PB samples of 20 CLL patients (14 without 
treatment and 6 under treatment) and 7 SLL patients (3 without treatment and 4 under 
treatment), by ELISA (Calbiochem, Dalmstadt, Germany), following the manufacturers’ 
protocol. 
 
Endothelial Differentiation Assays 
 
After detecting CEPC in PB samples we selected 4 SLL patients (3 without and 1 under 
treatment) and 4 CLL patients (3 without and 1 under treatment) to perform endothelial 
differentiation assays. Patients’ selection was based on the percentage of CEPC 
obtained in FACS analysis: SLL patients with more CEPC vs. CLL patients with more 
CEPC and SLL patients without CEPC vs. CLL patients without CEPC; without and 
under treatment. We used total MNC isolated from the same PB samples to perform 
these assays because of the low percentage of these progenitor cells and we verified 
the capacity of these cells to differentiate into endothelial cells in vitro.  
 
 
Endothelial differentiation culture conditions 
 
Isolated total MNC were cultured onto 2% gelatin coated 24 well-plates (5x105 
cells/well) and incubated in EPC differentiation medium: EBM-2 (Endothelial Cell Basal 
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Medium-2; Lonza), HEPES-buffered saline 1x (pH=8; GibcoBRL), FBS (Fetal Bovine 
Serum; Invitrogen), AA (Antibiotic and Antimicotic; Invitrogen), VEGF (Sigma), Heparin 
(Sigma), and ECGs (Endothelial Cell Growth Supplement, Sigma). Every 2 days, 1μl of 
VEGF (10μg/mL) and 1μl of Heparin (5000U/μL) were added to the cells. At the end of 
the differentiation assay, EC markers expression was determined by immunostaining 
with FVIII-related antigen (FVIII-ra) (1:100, Dako Cytomation M0616, clone F8/86) 
followed by goat anti-rabbit Alexa Fluor 594 (1:1000, Molecular Probes, Eugene, OR, 
USA). Cells were examined using a fluorescence microscope (x200 amplification; x 
400 amplification, EC-Plan-NEOFLUAR; Axioplan Microscope, Zeiss, Germany).  
 
Immunohistochemical staining of BM and LN sections 
 
Trephine BM (26 from CLL patients and 8 SLL patients) and LN biopsies (5 from CLL 
patients and 5 SLL patients) were assessed for routine histopathology, microvessel 
density (MVD) and CD38 tumor cell expression. Tissue samples were fixed in 10% 
formalin, BM biopsies were further decalcified in rapid bone decalcifier (Perudo00-008; 
Eurobio, Les Ulis, France), and paraffin embedded. Hematoxilin and eosin-stained 
sections were characterized for tumor cell distribution pattern in the BM 
(diffuse/nodular/interstitial) and lymph node (diffuse/proliferation centers). 
Immunohistochemistry was performed using automated immunohistochemical stainer 
(Techmate 500 Plus Dako, Dako Cytomation); tissue sections were incubated with 
mouse anti-human von Willebrand factor (Clone F8/86, 1:20, M0616, Dako 
Cytomation) and CD38 (Clone SPC32, 1:50, NCL-CD38-290, Novocastra), and 
immunodetection was performed with the ChemMate Dako EnVision detection kit 
(Dako Cytomation) employing Peroxidase/Diaminobenzidine. Vessels were counted in 
five high power fields (“hot spots”) (amplification: 200x) per biopsy and MVD expressed 
as the mean number of vessels per 0.72mm2. CD38 immunostaining was subjectively 
characterized by two independent observers according to staining intensity (no 
staining/staining low/medium/high) and distribution pattern (diffuse/proliferation 
centers). 
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TUNEL assay 
 
To assess cell apoptosis, analysis of DNA fragmentation by transferase-mediated 
dUTP nick-end labeling (TUNEL) was determined in the paraffin embedded BM (20 
from CLL patients and 7 SLL patients) and LN biopsies (3 from CLL patients and 5 SLL 
patients) using In Situ Cell Death Detection kit, POD (Roche Diagnostics, NJ, USA) 
and Histostain® Plus Broad Spectrum, DAB (Cat. No. 85-9643, Zymed Laboratories 
Inc., California, USA) kits following the manufacturer´s instructions with some 
modifications. BM and LN sections were analyzed by fluorescence and light 
microscopy. In both staining, for the quantification of positive cells in stained sections, 5 
high power fields (hpf) (400x amplification) with more stained nuclei were analyzed and 
the average of positive cells per biopsy determined.  
 
RNA Extraction  
 
Total RNA was extracted from the MNC that were previously isolated from the PB 
samples using the TRIZOL reagent (Invitrogen™) following the manufacturer’s protocol. 
 
miRNA microarrays  
 
Total RNA extracted as above was used for hybridization of miRNA probes (Exiqon). 
RNA concentrations were verified using the NanoDrop Spectrophotometer ND-1000 
(NanoDrop). To characterize and compare the miRNA expression profile of MNC 
isolated from the PB, a set of 37 RNA samples was divided in two RNA pools (30 
samples from CLL patients without treatment and 7 samples from SLL patients without 
treatment). The miRNA expression profile was performed using the miRCURY LNA 
(locked nucleic acid) array v.11.0 (Exiqon). 
Labeling and hybridization were performed as described by the manufacturers. One μg 
of total RNA of each sample was labeled (Hy3 or Hy5) using the miRCURY LNA 
microRNA Power labeling kit (Exiqon): CLL pool was labeled with Hy5 and SLL pool  
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was labeled with Hy3. The hybridized microarrays were washed, dried and scanned 
using a dual-laser Agilent Technologies scanner. 
Scanned images were analyzed using Feature Extraction Software (Agilent 
Technologies), which converts scanner-generated images into quantitative log ratios. 
Labeling efficiency was evaluated by the signals from the control spike-in capture 
probes. Background correction was performed using the Local Nearest Neighbor 
algorithm, which uses multiple local backgrounds in the neighborhood of a given spot 
to serve as background signal for that feature. Expression values were presented as 
log ratio of red signal/green signal. For accuracy of the log ratios calculation, dye 
normalization was performed using the Feature Extraction Software. Log ratio errors 
and associated p-values, which determines the probability of that a log ratio is 
significantly different from zero, were also calculated. 
 
 
Analysis of the microarrays 
 
Expression values (log ratios) extracted from the Feature Extraction Software were 
analyzed for 1.8 fold changes in expression. Threshold of miRNAs expression for 
analysis was calculated using Power 2 average of log ratio. Using this threshold only 
the differentially expressed microns were analyzed. TIGR Multiple Experiment Viewer 
software package (MeV version 4.1) was used to perform data analysis and visualize 
the results. 
 
 
cDNA synthesis and qRT-PCR 
 
cDNA was synthesized from 1μg of total RNA from CLL and SLL pools, using the 
NCode™ miRNA first-strand synthesis (Invitrogen™). This method provides the 
polyadenylation of mature microRNAs of total RNA and synthesis of cDNA from the 
tailed miRNAs using SuperScript™ III RT and a universal RT Primer provided. 
MicroRNAs were quantified by quantitative RT-PCR (qPCR) with SYBR Green 
(Invitrogen™) using a Universal qPCR primer provided and primers to target specific  
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miRNAs in ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). 
Two μl of diluted cDNA (1:2) was used as template in 20μL qPCR reactions with 10 μM 
of each primer and 1x Platinum SYBR Green qPCR Super Mix-UDG. Thermocycling 
parameters were: 50°C for 2 min; 95°C for 10 min; 40 cycles of 95°C for 15 s, 60°C for 
1 min; 95°C for 15 s, 60°C for 15 s, and 95°C for 15 s. Negative controls were water 
(no cDNA). The human 18S rRNA was used as endogenous control to normalize RNA 
input levels.  
Relative expression was calculated using the comparative method 2-ΔΔCt. Primers used 
in the qRT-PCR reactions are listed on Supplementary Table 5. 
 
 
Bioinformatic Integration of mRNA and miRNA Expression Data 
 
The predicted targets for each miRNA selected for further analyses were performed 
using the databases available online: miRanda and miRBase (microrna.sanger.ac.uk), 
TargetScan (www.targetscan.org), DIANA microT (diana.pcbi.upenn.edu) and PicTar 
(pictar.bio.nyu.edu). 
 
 
Statistical analysis 
 
Results are expressed as mean ± standard deviation (SD). Data were analyzed using 
the GraphPad Prism v. 5.0 (GraphPad Software). Statistical significance of differences 
was assessed by unpaired two-tailed Student’s t test and Mann Whitney two-tailed test. 
Results from the correlation between VEGF plasma levels and the percentage of 
CEPC were assessed with the nonparametric correlation (Spearman test) and the level 
of significance was set at Spearman r ≥ 0.95 and p < 0.05. p values of less than 0.05 
were considered statistically significant. 
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The patients were divided into 4 groups, according to the phase of the disease 
(leukemia vs. lymphoma presentation) and clinical treatment after the diagnosis 
(without treatment and under treatment, mostly with chemotherapy). All the subsequent 
analysis was performed with the aim of comparing CLL patients vs. SLL patients, 
without treatment vs. under treatment. 
 
 
Quantification of EPC in PB samples from CLL and SLL patients 
 
As determined by FACS analysis, performed with the software FlowJo version 7.2.5 
(Supplementary Tables 1,2,3,4; Supplementary Figure 1), 46/60 (77%) of the 
patients studied had CEPC (CD133+KDR+ cells). CLL patients had more CEPC-positive 
samples (50%) than SLL patients (27%). 
Our results suggest significant differences between the percentage of CEPC in SLL 
patients without treatment vs. CLL patients without treatment (p<0.05), verified by a 
higher percentage of EPC in the circulation of SLL patients without treatment (Figure 
2). Interestingly, the group of SLL patients under treatment had the highest number of 
CEPC in PB. These results show that patients with SLL have higher number of 
circulating EPC, regardless of their treatment status. 
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Figure 2. CEPC in PB of SLL and CLL patients. The percentage of circulating EPC was 
determined by flow cytometry analysis. Average values are represented and associations 
between variables (SLL and CLL; without and under treatment) were evaluated by 
Student’s t test and Mann Whitney test. 
 
 
CEPC correlate with VEGF plasma levels 
 
Levels of circulating VEGF, measured in plasma samples, were higher in SLL patients 
than in CLL patients under treatment (126,6±140,3pg/mL (n=4) vs. 65,38±33,76pg/mL 
(n=6), respectively), but the opposite occurred in patients without treatment 
(43,74±13,08pg/mL (n=3) vs. 70,09±60,93pg/mL (n=14), SLL patients vs. CLL patients, 
respectively) (Figure 3). 
These data suggest that in the patients studied, VEGF plasma levels do not vary, 
regardless of the phase of the disease (SLL vs. CLL) and of the treatment status. 
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Figure 3. Circulating VEGF measured in plasma samples from SLL and CLL patients; 
both without and under treatment. Average values are represented and the comparison 
between the two groups SLL and CLL in the same clinical situation was evaluated by Mann 
Whitney test. 
 
A comparison was made between the percentage of CEPC and the VEGF plasma 
levels both obtained from PB samples. The results indicate no correlation between the 
two angiogenesis-related parameters and the two phases of the disease (Figure 4B; 
Figure 5B), confirmed with the nonparametric Spearman test. 
Results suggest that CEPC are increased in SLL patients in both groups (without and 
under treatment), but no correlation was verified between VEGF plasma levels and 
CEPC in these patients (Figure 4B; Figure 5B). 
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Figure 4 A, B. Correlation between angiogenic cytokines (VEGF plasma levels) and 
CEPC in patients without treatment (CLL patients n=14 and SLL patients n=3). 
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Figure 5 A, B. Correlation between angiogenic cytokines (VEGF plasma levels) and 
CEPC in patients under treatment (CLL patients n=6 and SLL patients n=4). 
 
 
 
 
38 
 
Results
 
 
CEPC differentiate into functional endothelial cells 
 
To validate the importance of circulating EPC in CLL and to prove their endothelial 
potential we cultured EPC in well established endothelial differentiation assays.   
At the end of the endothelial differentiation assay (4 weeks) the differentiated cells 
show endothelial morphology and express endothelial-specific markers (VWF+ cells). 
From the 8 patients selected we only observed the differentiation of endothelial cells in 
2 patients: one of the CLL patients with more CEPC (under treatment) (Figure 6A) and 
one of the SLL patients without CEPC (without treatment) (Figure 6B). 
 
 
     
 
 
Figure 6 A. Endothelial differentiation observed in EPC isolated from CLL patient 
under treatment (x400 amplification) and in (B) EPC isolated from SLL patient 
without treatment (x200 amplification). 
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Microvessel density, tumor cell apoptosis and CD38 expression by CLL cells in 
BM and LN biopsies allows differentiating SLL from CLL phases. 
 
Having studied the angiogenesis-related parameters in circulation, we next quantified 
the angiogenic index (number of vessels per five high power fields). We also evaluated 
cell apoptosis (number of apoptotic cells per five high power fields) and CD38 tumor 
cell expression in each BM and LN section. 
 
We quantified more vessels in BM biopsies from SLL patients than in BM sections from 
CLL patients (p<0.05, Unpaired t test). This observation could be related with a more 
aggressive phenotype (Figure 7). 
Taken together, these data suggest that the higher percentage of CEPC quantified in 
SLL patients could be related with increased microvessel density in BM biopsies 
observed (Figure 8 A). 
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Figure 7. Microvessel density was quantified in SLL and CLL biopsies (BM and LN) 
after immunohistochemical staining for blood vessels (Factor VIII). Values represent 
the median vessel score determined as the average number of blood vessels detected in 
five high power fields (hpf = 400x magnification) per biopsy. 
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Figure 8. MVD in BM and LN of SLL patients assessed by immunohistochemistry for 
vWf in paraffin-embedded sections. A) BM trephine biopsy (x400 amplification). B) LN 
trephine biopsy (x400 amplification).       
 
 
As determined by TUNEL staining, BM biopsies from CLL patients had higher number 
of tumor cell apoptosis when compared with BM biopsies from SLL patients. LN 
biopsies from the 2 groups (CLL and SLL) showed a similar average of apoptotic cells 
per biopsy (Figure 9). 
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Figure 9. Tumor Cell apoptosis in BM and LN sections assessed by TUNEL staining. 
Average values per biopsy (BM and LN) are represented. 
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Figure 10. Apoptotic cells (green nuclei) in LN biopsies from CLL and SLL patients 
(A, C; respectively) and in BM biopsies from CLL and SLL patients (B, D; 
respectively) (x 400 amplification). 
 
 
The results suggest no differences between the CD38 staining in the distribution 
pattern observed in LN from SLL vs. CLL patients, but the staining intensity observed in 
these biopsies were higher in SLL patients (Figure 11A). In the BM biopsies we 
observed that almost all biopsies from CLL patients were negative for CD38 staining 
and again the CD38 staining intensity was higher in the BM biopsies of SLL patients 
(Figure 11B).  
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Figure 11 A. Characterization of CD38 tumor cell expression in LN biopsies from SLL 
and CLL patients. + (positive); +/- (more or less); - (negative). 
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Figure 11 B. Characterization of CD38 tumor cell expression in BM biopsy samples from 
SLL and CLL patients. + (positive); +/- (more or less); - (negative). 
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Figure 12. CD38 tumor cell expression in BM and LN of SLL patients assessed by 
immunohistochemistry for CD38 in paraffin-embedded sections. A) BM trephine 
biopsy (x400 amplification). B) LN trephine biopsy (x400 amplification).       
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MicroRNA profiling of lymphoma and leukemic “stages” of Chronic Lymphocytic 
Leukemia 
 
The miRNA expression profile of MNC isolated from the PB of 30 CLL patients and 7 
SLL patients, both without treatment, showed that there are different miRNA patterns 
associated with these two forms of the disease. From a total of 7076 miRNAs probes 
(including 4 replicates per probe) and using Feature Extraction Software we obtained 
1430 miRNAs up-regulated and 1213 miRNAs down-regulated in CLL (Figure 13).  
 
 
 
Figure 13. Spatial Distribution of Significantly Up-Regulated and Down-Regulated 
miRNAs using Feature Extraction Software. 
 
As miRNA probes were replicated four times per array, the average of the signal 
intensities for each miRNA, expressed as log ratio between Hy5 and Hy3, were 
calculated and the resulting signal intensities expressed as average of log ratio. The 
variability between signal intensities for miRNAs replicates, given by standard error of 
the mean, was low for CLL pool, while the SLL pool generated average of log ratios 
characterized by higher variability, which may be the result of poor RNA quality and 
quantity in SLL samples. 
From the range of signal intensities obtained, a miRNA was considered up-regulated 
when expression crosses a threshold of 1.8 fold-variation. Using this cutoff, 39 miRNAs 
up-regulated in CLL were obtained. The most up-regulated miRNAs in CLL were miR- 
 
(1213) 
(1430)
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142-3p, miR-29b and miR-30e which were about 2.8 times more expressed in CLL 
than in SLL samples (Supplementary Figure 2). 
A miRNA was considered down-regulated when expression crosses a threshold of 0.5 
fold-variation (half of the expression). Using this cutoff, 15 miRNAs down-regulated in 
CLL were analyzed. The most down-regulated miRNAs in CLL were miR-1277, miR-
581, miR-548o and miR-942 which were about 0.6 times less expressed in CLL than in 
SLL samples (Supplementary Figure 3). 
MicroRNAs were considered differentially expressed for a threshold of 1.8, where 
expression values given by the average of log ratio with 1.8 fold-variations were 
analyzed. Differentially expressed miRNAs using this threshold were clustered using 
hierarchical unsupervised average linkage and Euclidean distances. Based on the 
defined threshold, 54 miRNAs were differentially expressed in CLL vs. SLL. In red are 
listed the miRNAs up-regulated in CLL and in green miRNAs up-regulated in SLL 
(Figure 14).  
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Figure 14. Microarray profiling of 54 miRNAs differentially expressed in CLL and 
SLL. Unsupervised average linkage hierarchical clustering (Euclidean distance) was 
performed. The color display encodes the logarithm of the expression changes, where 
varying shades of red and green indicate up and down regulation in CLL and the opposite 
in SLL.  
 
 
To validate the results of miRNA microarrays we performed qRT-PCR for 11 miRNAs 
up-regulated in CLL pool and seven miRNAs down-regulated in SLL pool. From the 
microarrays expression data we have identified miR-1277 and miR-1202 as the most 
down-regulated miRNAs in CLL, while miR-142-3p, miR-19a, miR-155 and miR-451 
were the most up-regulated miRNAs in CLL (Figure 16).   
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Figure 16. Expression of miRNA by qRT-PCR: down-regulated and up-regulated 
miRNAs in CLL vs. SLL pools. Relative mRNA expression was evaluated in MNC 
isolated from PB samples derived from CLL and SLL patients. Most down-regulated and 
up-regulated miRNAs in CLL are identified by arrows. 
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Some problems were encountered during the progression of this M.Sc. thesis. The 
access to case study material was restricted to the patients’ routine follow up, and so 
the number of samples available for the study was limited. Since the diagnosis of CLL 
is mainly based on PB analysis (flow cytometry, cytogenetic analysis and complete 
blood cell count), access to fresh BM and LN biopsy samples was null, for which it was 
not possible to evaluate cytokine levels/cell counts or perform RNA extraction from 
these tissues. An upgrade of the present work would certainly be to match the results 
obtained here for the PB with those of the organs involved in this disease, BM and LN. 
What also has to be taken into account is that this work is based on a complex 
biological system, the human body, and the variability in this system is high, especially 
when dealing with one disease that has distinct and poorly defined clinical stages. The 
patient’s classification and stratification in the different groups is therefore subjective; 
CLL has a variable course and the same patient can present the 2 phases at different 
time-points (Ray et al., 1975). The criterion taken into account here, to stratify the 
patients, was the lymphocyte count in the PB per total white blood cells/μL, at the day 
of sample collection.  
 
This thesis brought new highlights in the understanding of the importance of 
angiogenesis/vasculogenesis role in CLL/SLL, namely the possibility of using EPC PB 
counts as a surrogate marker to distinguish the two phases of this disease. Patients 
with higher percentage of these progenitors in circulation could be considered to have 
SLL presentation.  
In this disease, tumor cell mass (tumor volume) is similar, regardless the phase (SLL 
vs. CLL) or treatment status, and so it was not surprising to find no differences in VEGF 
plasma levels.  
Furthermore, these circulating EPC show the ability to differentiate into mature 
endothelial cells, which actually suggests that these are functional cells and can 
incorporate into sites of vasculogenesis (Peters et al., 2005).  
When looking to the target organs of this disease, other angiogenesis-related 
parameters were assessed, and, as shown in previous studies on lymphoblastic 
leukemia (Perez-Atayde et al., 1997; Kini et al., 2000), increased microvessel density 
was observed in the BM biopsies of SLL patients, when compared to CLL. 
Other than angiogenesis, we also focused on the tumor cell itself. Tumor cell apoptosis 
and the CD38 expression were therefore assessed. Given that CLL cells are resistant  
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to apoptosis (Reed, 1999) and, as known from previous studies, patients with higher 
CD38 tumor cell expression have worse prognosis and show increased resistance to 
the therapies (Matrai, 2005), the decreased tumor cell apoptosis and higher CD38 
expression observed here, in the BM of SLL patients, can be in fact predictive of a 
more aggressive disease, with worse prognosis, when compared to the leukemic 
phase. 
To compare the differences in microRNAs expression profiles in the total mononuclear 
PB cells from CLL and SLL patients, microarrays of microRNAs were performed. The 
miRNA microarrays are a powerful technique that allowed us to look at all miRNAs 
known so far and published in miRBase (http://microrna.sanger.ac.uk) identified in 
human, rat and mice, simultaneously in a single experiment. Although the results 
obtained are very preliminary, it was possible to observe that CLL and SLL have 
different miRNAs expression profiles, further validation studies are required.  
Some of the most up-regulated miRNAS in CLL, found in this study, were previously 
identified, as miR-15a, miR-155, miR-16 (Calin et al., 2002). Interestingly, we identified 
newly up-regulated miRNAs in CLL as miR-142-3p which expression was validated by 
qRT-PCR. From the miRNAs down-regulated in CLL vs. SLL, we validate the miRNAs 
miR-1277 and miR-1202, which their role in disease or other biological process were 
not yet described. 
As future work we intend to perform in vitro and in vivo studies to validate miRNA 
putative targets and explore the biological significance of the differences observed.  
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Figure 1. Quantification of circulating EPC in CLL patients without and under 
treatment (A, C; respectively) and SLL patients without and under treatment (B, D; 
respectively). To identify CEPC, PB cells were analyzed for the presence of CD133 and 
KDR antigens by flow cytometry. These plots show representative data from four of the 
analyzed patients. 
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Supplementary Table 1. Parameters quantified in PB samples from CLL patients 
without treatment in this study.  
 
Lymphocyte count in the PB per total white blood cells/μL; total MNC isolated from PB samples; 
Percentage of CEPC; VEGF systemic levels. M: male; F: female; ND: not determined. 
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Supplementary Table 2. Parameters quantified in PB samples from SLL patients 
without treatment in this study.  
 
 
 
Lymphocyte count in the PB per total white blood cells/μL; total MNC isolated from PB samples; 
Percentage of CEPC; VEGF systemic levels. M: male; F: female; ND: not determined. 
 
 
 
Supplementary Table 3. Parameters quantified in PB samples from CLL patients 
under treatment in this study.  
 
 
Lymphocyte count in the PB per total white blood cells/μL; total MNC isolated from PB samples; 
Percentage of CEPC; VEGF systemic levels. M: male; F: female; ND: not determined. 
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Supplementary Table 4. Parameters quantified in PB samples from SLL patients 
without treatment in this study.  
. 
 
Lymphocyte count in the PB per total white blood cells/μL; total MNC isolated from PB samples; 
Percentage of CEPC; VEGF systemic levels. M: male; F: female; ND: not determined. 
 
 
 
Supplementary Table 5. Nucleotide sequences of the primers used in the qRT-
PCR reactions. 
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Figure 2. miRNAs up-regulated in CLL vs. SLL. 
 
 
 
 
 
Figure 3. miRNAs down-regulated in CLL vs. SLL. 
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FACS staining 
 
• Use 200μL of PB to perform the FACS staining, 100μL as control and 100μL for the 
staining. 
• Add 5μL of FcR blocking solution and incubate 10 min at room temperature (RT) 
• Add 5μL of human KDR antibody and incubate for 25 min at 4ºC in the dark with 
agitation 
• Add 5μL of human CD133 antibody and incubate for 20 min at 4ºC in the dark with 
agitation 
• Dilute the sample in 2mL of BD FACS lysing solution to lyse the red blood cells. 
Incubate for 10 min on ice and centrifuge at 1200 rpm for 5 min 
• Wash with 2mL of PBS/FBS (2%) and centrifuge at 1200 rpm for 5 min 
• Resuspend in 200μL of PBS/FBS (2%) and analyse by flow cytometry. 
 
 
Plasma separation 
 
• Transfer the blood into a 15mL Falcon tube 
• Centrifuge at 1500 rpm for 7 min 
• Collect the plasma to a 2mL eppendorf tube 
  
 
Isolation of MNC 
 
• Dilute blood sample 1:3 in PBS/EDTA 2mM 
• Slowly pour on a 2 mL cushion of Lymphoprep (Ficoll gradient) in 15mL Falcon tubes 
• Centrifuge at 1800 rpm for 30 min 
• Isolate the mononuclear cells (interface ring) with a plastic pipette, transfer to a new 
falcon tube and add the same volume of PBS/EDTA 2mM 
• Count the cells with a Neubauer Chamber  
• Centrifuge at 1200 rpm for 5 min 
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TUNEL assay 
 
• Rehydration 
 
• Dewax paraffin embedded sections in xylene and rehydrate in graded ethanol series to 
water.  
o Xylene for 15 min 
o Xylene for 15 min 
o Absolute ethanol for 10 seconds 
o 90% ethanol for 10 seconds 
o 70% ethanol for 10 seconds 
o dH2O 1 time for 5 min 
• Wash with PBS 3 times for 5 min 
• Proteinase digestion 
 
• Permeabilization of tissue with 20μg/mL Proteinase K in 10mM Tris/HCl. Incubate for 20 
min at 37ºC  
 
• Additional permeabilization with 0.1% Triton X-100 in 0.1% Sodium citrate freshly 
prepared. Incubate for 10 min at RT 
 
• Wash with PBS 3 times for 5 min 
 
TUNEL Labeling 
• Prepare labeling Mix just before the experiment: 50 μL Enzyme solution + 450 μL 
labeling solution (save 50μL labeling solution for negative control). Cover with parafilm 
pieces. Be careful that there are no bubbles trapped underneath the parafilm, and that 
the parafilm pieces covering test and control sections do not touch. 
 
• Incubate in humidified chamber for 1h15 at 37ºC in dark. 
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• Remove parafilm coverslips off the sections by pipeting PBS around the edge of 
parafilm until it floats, and then lift it with tweezers. 
 
 
• Wash with PBS 3 times for 5 min in dark 
 
• Analysis of samples by fluorescence microscopy and check staining under FITC cube. 
 
 
 
 
 
 
 
 
 
 
 
 
 
